TABLE 4.
Routine investigations to be performed on the exposed individual.
| Test | Baseline | 6 weeks | 3 months |
|---|---|---|---|
| HIV |
|
|
|
|
|
|
|
| HBV | HBsAb‡ | - | HBsAg‡ |
| HCV | HCV Ab§ | HCV PCR§ | - |
| Syphilis | If sexual exposure or source positive for syphilis, TP Ab/RPR | - | TP Ab/RPR¶ |
| Creatinine | If TDF part of PEP | - | - |
| FBC and differential¶ | In child if zidovudine prescribed as PEP | - | - |
| Pregnancy (if appropriate)†† | βHCG | βHCG | - |
ELISA, enzyme-linked immunosorbent assay; HBV, hepatitis B virus; HBsAb, hepatitis B surface antibody; HBsAg, hepatitis B surface antigen; HCV, hepatitis C virus; HCV Ab, hepatitis C virus antibody; PCR, polymerase chain reaction; TP Ab, Treponema pallidum antibody; RPR, rapid plasma regain; FBC, full blood count; TDF, tenofovir disoproxil fumarate; PEP, post-exposure prophylaxis.
5th-generation ELISA may also be used.
Can be omitted if exposed individual is known to be immune to HBV (through infection or vaccination).
Only if source is HCV Ab positive or unknown and at high risk of HCV infection.
Repeat after 2 and 4 weeks in child on zidovudine.
In adolescents, this should be done if individual is Tanner stage 3 or greater.